Rabies Virus, High Cell Passage-Street Alabama Dufferin Strain

Verify with FDA CVM →

46 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
46
Total Reports
3
Deaths Reported
650.0%
Death Rate

Active Ingredients

Rabies Virus, High Cell Passage-Street Alabama Dufferin Strain

Administration Routes

SubcutaneousUnknownIntramuscular

Species Affected

Dog 37
Cat 9

Most Affected Breeds

Retriever - Labrador 6
Domestic Shorthair 5
Pit Bull 4
Chihuahua 4
Dachshund (unspecified) 4
Domestic Longhair 3
Crossbred Canine/dog 2
Terrier (unspecified) 2
Bulldog - French 2
Poodle - Miniature 1

Most Reported Reactions

Vomiting 12
Lethargy (see also Central nervous system depression in Neurological) 10
Facial swelling (see also Skin) 6
Injection site swelling 6
Hives (see also Skin) 5
Not eating 5
Other abnormal test result NOS 5
Lack of efficacy (endoparasite) - heartworm 4
Pale mucous membrane 4
Injection site sarcoma 4
Injection site lump 4
Reluctant to move 3

Outcome Breakdown

Recovered/Normal
17 (37.0%)
Outcome Unknown
15 (32.6%)
Ongoing
11 (23.9%)
Euthanized
2 (4.3%)
Died
1 (2.2%)

Data Summary

Metric Value
Total adverse event reports 46
Reports involving death 3
Case-fatality rate (reported events) 650.0%
Distinct species in reports 2
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Rabies Virus, High Cell Passage-Street Alabama Dufferin Strain Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 46 adverse event reports referencing Rabies Virus, High Cell Passage-Street Alabama Dufferin Strain, including 3 reports in which the animal died — a 650.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Rabies Virus, High Cell Passage-Street Alabama Dufferin Strain. Reported administration routes include Subcutaneous, Unknown, Intramuscular. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Rabies Virus, High Cell Passage-Street Alabama Dufferin Strain reports are Dog (37 reports), Cat (9 reports), with Dog accounting for the largest share. Within those species, Retriever - Labrador (6), Domestic Shorthair (5), Pit Bull (4) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Rabies Virus, High Cell Passage-Street Alabama Dufferin Strain are Vomiting (12), Lethargy (see also Central nervous system depression in Neurological) (10), Facial swelling (see also Skin) (6), Injection site swelling (6). Of the 46 reports with a coded outcome, Recovered/Normal is the leading category at 37.0%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Rabies Virus, High Cell Passage-Street Alabama Dufferin Strain.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial